Case | HBS Case Collection | 2006
by Malcolm P. Baker, Chris Lombardi and Aldo Sesia
Hedge fund SAC Capital and analysts from Gradient Analytics and Banc of America face charges of stock price manipulation from Biovail, a Canadian pharmaceutical company. Gradient and BofA produced negative reports on Biovail's earnings quality. At the same time, SAC built a large short position in the stock. The defendants must consider specific and general strategic responses to these allegations.
Keywords: Stock Shares; Investment Banking; Asset Pricing; Financial Strategy; Crime and Corruption; Pharmaceutical Industry; Financial Services Industry; Canada;
Citation:
Baker, Malcolm P., Chris Lombardi, and Aldo Sesia. "Selling Biovail Short." Harvard Business School Case 207-071, November 2006.
View Profile »View Publications »
Working Paper | 2013
Do Strict Capital Requirements Raise the Cost of Capital? Banking Regulation and the Low Risk Anomaly
Malcolm Baker and Jeffrey Wurgler
Case | HBS Case Collection | 2012
Restructuring at Nova Chemical Corporation (Abridged)
Scott P. Mason and Malcolm Baker
Teaching Note | HBS Case Collection | 2012 (Revised from original 2006 version)
Wells Fargo Convertible Bonds (TN)
Malcolm P. Baker
Keywords: Financial Services Industry;